Dynavax Technologies in a press release today announced they have selected the first participants in their Phase 1 safety study of a COVID-19 vaccine in production by China-based Clover Pharmaceuticals.
See our vaccine tracker where we track the daily status of every COVID-19 vaccine manufacturer.
We last reported on Dynavax at the end of May for posting a more than 25% stock price increase following the announcement of a partnership with Sinovac Biotech.
In the partnership, Dynavax acts as the supplier of a proprietary toll-like receptor 9 (TLR9) agonist adjuvant CpG 1018. Clover's vaccine, called SCB-2019, is based on a proprietary vaccine technology called "Trimer-Tag©."
In the Phase 1 trial, the company will be testing "safety, reactogenicity, and immunogenicity of SCB-2019." The tests will comprise 90 adults tested for fitness spanning ages 18 to 54 years. A separate, elderly group of 60 individuals between 55 to 75 years old will be tested separately.
“We are proud to contribute CpG 1018 to this global effort to rapidly develop an adjuvanted vaccine to prevent COVID-19,” said Dynavax CEO Ryan Spencer, “CpG 1018’s ability to enhance the immune response, as successfully demonstrated in HEPLISAV-B, is expected to reduce the dose of antigen needed, helping ensure broader availability to patients. Additionally, an adjuvanted vaccine may be especially important for older adults and people with chronic conditions who are traditionally less responsive to vaccination and have the greatest risk of severe disease and death from COVID-19.”